-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumor is a disease that manifests locally and affects the whole body.
Because the early symptoms are not obvious, many patients are already at an advanced stage when they are found.
Relevant data show that advanced tumors account for about 70% of malignant tumors
.
Such patients have an urgent need for treatment.
Against this background, the upsurge in cancer treatment research continues to emerge.
Cellular immunotherapies, including PD-1/PD-L1 therapy, have mushroomed, bringing hope to the majority of patients
.
Since 2022, there has been continuous good news in the domestic treatment field for advanced tumors, and a number of new drugs and inhibitors have been approved for clinical use, involving pharmaceutical companies such as Fosun Pharma and Betta Pharmaceuticals
.
For example, on January 19, Fosun Pharma announced that HLX208, a small-molecule inhibitor targeting human BRAF protein V600E mutation, has been approved for clinical trials of single-agent or combination therapy for advanced solid tumors
.
Henlius intends to conduct Phase Ib/II clinical trials of the new drug as a single drug or combination therapy in China (excluding Hong Kong, Macau and Taiwan) when conditions are met
.
The BR105 injection of Borui Bio has also been approved for clinical use in advanced tumors
.
According to the introduction of borui biology, BR105 is a humanized monoclonal antibody targeting SIRPα developed by it, which has better safety than targeting CD47, and also has anti-PD-1/PD-L1 antibodies The potential of combined use of T-cell immune checkpoint inhibitors, in addition to synergistic effects with antibodies targeting tumor-associated antigens (TAA), can further enhance the killing effect of immune cells mediated by TAA antibodies on tumors
.
Preclinical studies have shown that BR105 has an excellent safety profile and can bind to different variants of SIRPα, block the interaction between CD47 and SIRPα, and does not affect the T cell activation signal involved in SIRPγ
.
Euho Pharma's YH004 injection was approved for clinical use in China for locally advanced or metastatic malignant tumors
.
This product is a humanized monoclonal antibody targeting 4-1BB under development
.
Preclinical experiments show that YH004 alone and in combination with anti-PD-1 antibodies has significant immunomodulatory activity and anti-tumor activity, and is safe and well tolerated
.
Connoya Bio's CM350 has been approved for clinical use in China and is indicated for advanced malignant solid tumors
.
This product is a bispecific antibody of Glypican 3 (GPC3) × CD3 independently developed by the company
.
Preclinical studies have shown that CM350-induced TDCC can effectively kill GPC3-positive tumor cells, and there is no risk of non-specific cytokine release in the absence of target cells, indicating that it may provide patients with better efficacy and controllable safety
.
In addition, on January 20, the drug clinical trial registration and information publicity platform showed that Hengrui Medicine registered the phase I clinical study of CD112R/TIGIT dual anti-SHR-2002, which is intended to evaluate the candidate drug alone or in combination with other anti-tumor treatments.
Safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignant tumors; on the same day, Junjing Bio's XPO1 inhibitor WJ01075 was approved for clinical use in advanced malignant tumors
.
In addition to local pharmaceutical companies, imported drugs also have new clinical progress.
For example, DS-1062a, which was declared by Daiichi Sankyo, has recently obtained an implied license for clinical trials, and the indication is advanced solid tumors
.
Previously, the product has obtained implied licenses for a number of clinical trials, including indications for breast cancer, non-small cell lung cancer,
etc.
In general, drug research and development in the field of advanced tumor treatment is advancing continuously.
With the approval of these products for clinical use, if the follow-up progress can be carried out smoothly, it will further benefit the majority of patients with advanced tumors
.
Because the early symptoms are not obvious, many patients are already at an advanced stage when they are found.
Relevant data show that advanced tumors account for about 70% of malignant tumors
.
Such patients have an urgent need for treatment.
Against this background, the upsurge in cancer treatment research continues to emerge.
Cellular immunotherapies, including PD-1/PD-L1 therapy, have mushroomed, bringing hope to the majority of patients
.
Since 2022, there has been continuous good news in the domestic treatment field for advanced tumors, and a number of new drugs and inhibitors have been approved for clinical use, involving pharmaceutical companies such as Fosun Pharma and Betta Pharmaceuticals
.
For example, on January 19, Fosun Pharma announced that HLX208, a small-molecule inhibitor targeting human BRAF protein V600E mutation, has been approved for clinical trials of single-agent or combination therapy for advanced solid tumors
.
Henlius intends to conduct Phase Ib/II clinical trials of the new drug as a single drug or combination therapy in China (excluding Hong Kong, Macau and Taiwan) when conditions are met
.
The BR105 injection of Borui Bio has also been approved for clinical use in advanced tumors
.
According to the introduction of borui biology, BR105 is a humanized monoclonal antibody targeting SIRPα developed by it, which has better safety than targeting CD47, and also has anti-PD-1/PD-L1 antibodies The potential of combined use of T-cell immune checkpoint inhibitors, in addition to synergistic effects with antibodies targeting tumor-associated antigens (TAA), can further enhance the killing effect of immune cells mediated by TAA antibodies on tumors
.
Preclinical studies have shown that BR105 has an excellent safety profile and can bind to different variants of SIRPα, block the interaction between CD47 and SIRPα, and does not affect the T cell activation signal involved in SIRPγ
.
Euho Pharma's YH004 injection was approved for clinical use in China for locally advanced or metastatic malignant tumors
.
This product is a humanized monoclonal antibody targeting 4-1BB under development
.
Preclinical experiments show that YH004 alone and in combination with anti-PD-1 antibodies has significant immunomodulatory activity and anti-tumor activity, and is safe and well tolerated
.
Connoya Bio's CM350 has been approved for clinical use in China and is indicated for advanced malignant solid tumors
.
This product is a bispecific antibody of Glypican 3 (GPC3) × CD3 independently developed by the company
.
Preclinical studies have shown that CM350-induced TDCC can effectively kill GPC3-positive tumor cells, and there is no risk of non-specific cytokine release in the absence of target cells, indicating that it may provide patients with better efficacy and controllable safety
.
In addition, on January 20, the drug clinical trial registration and information publicity platform showed that Hengrui Medicine registered the phase I clinical study of CD112R/TIGIT dual anti-SHR-2002, which is intended to evaluate the candidate drug alone or in combination with other anti-tumor treatments.
Safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignant tumors; on the same day, Junjing Bio's XPO1 inhibitor WJ01075 was approved for clinical use in advanced malignant tumors
.
In addition to local pharmaceutical companies, imported drugs also have new clinical progress.
For example, DS-1062a, which was declared by Daiichi Sankyo, has recently obtained an implied license for clinical trials, and the indication is advanced solid tumors
.
Previously, the product has obtained implied licenses for a number of clinical trials, including indications for breast cancer, non-small cell lung cancer,
etc.
In general, drug research and development in the field of advanced tumor treatment is advancing continuously.
With the approval of these products for clinical use, if the follow-up progress can be carried out smoothly, it will further benefit the majority of patients with advanced tumors
.
